Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks. by Mallm, J.P. et al.
Article
Linking aberrant chromatin features in chronic
lymphocytic leukemia to transcription factor
networks
Jan-Philipp Mallm1,a, Murat Iskar2,a, Naveed Ishaque3,†,a, Lara C Klett1,4, Sabrina J Kugler5,6, Jose M
Muino7,‡ , Vladimir B Teif8 , Alexandra M Poos1,4,9,10, Sebastian Großmann1,§, Fabian Erdel1,11 ,
Daniele Tavernari1,¶ , Sandra D Koser12, Sabrina Schumacher1, Benedikt Brors12, Rainer König9,10,
Daniel Remondini13 , Martin Vingron7, Stephan Stilgenbauer6,††, Peter Lichter2,14, Marc Zapatka2 ,
Daniel Mertens5,6,*,b & Karsten Rippe1,**,b
Abstract
In chronic lymphocytic leukemia (CLL), a diverse set of genetic
mutations is embedded in a deregulated epigenetic landscape that
drives cancerogenesis. To elucidate the role of aberrant chromatin
features, we mapped DNA methylation, seven histone modifi-
cations, nucleosome positions, chromatin accessibility, binding of
EBF1 and CTCF, as well as the transcriptome of B cells from CLL
patients and healthy donors. A globally increased histone deacety-
lase activity was detected and half of the genome comprised
transcriptionally downregulated partially DNA methylated domains
demarcated by CTCF. CLL samples displayed a H3K4me3 redistribu-
tion and nucleosome gain at promoters as well as changes of
enhancer activity and enhancer linkage to target genes. A DNA
binding motif analysis identified transcription factors that gained
or lost binding in CLL at sites with aberrant chromatin features.
These findings were integrated into a gene regulatory enhancer
containing network enriched for B-cell receptor signaling pathway
components. Our study predicts novel molecular links to targets of
CLL therapies and provides a valuable resource for further studies
on the epigenetic contribution to the disease.
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Introduction
Genomic sequence analysis has identified a comprehensive set of
leukemogenic candidate genes in chronic lymphocytic leukemia (CLL;
Martin-Subero et al, 2013; Landau et al, 2015; Puente et al, 2015).
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However, how these genetic changes drive the cellular and clinical
pathophenotype of the disease is currently an open question (Zenz
et al, 2010; Kipps et al, 2017). The complex molecular pathogenesis of
CLL involves microenvironmental stimulation via aberrant signaling
including the B-cell receptor (BCR), NF-jB, IL-4, and TLR pathways,
among others (Abrisqueta et al, 2009; Zenz et al, 2010; Hallek, 2015;
Stilgenbauer, 2015; Kipps et al, 2017). The relevance of BCR signaling
in CLL is underlined by the clinical success of BCR signaling inhibitors
like ibrutinib (Byrd et al, 2013; Burger et al, 2015) and idelalisib
(Furman et al, 2014), and by the prognostic impact of somatic hyper-
mutations and the gene usage of the immunoglobulin itself (Zenz et al,
2010; Duhren-von Minden et al, 2012). Remarkably, apart from a
biased usage of the immunoglobulin genes and mutations in the BCR
complex in a specific small subset of CLL patients, there are no recur-
rent genetic mutations within the components of the BCR signaling
cascade. Rather, CLL cells display a massive global transcriptional
deregulation that is affecting intracellular pathways and microenviron-
mental signaling toward cellular survival (Burger & Chiorazzi, 2013).
Thus, it appears that a diverse set of genetic lesions conspires with
epigenetic aberrations to drive cancerogenesis in a manner that is only
partially understood. The relevance of deregulated epigenetic signaling
for CLL is apparent from a number of findings. Epigenetic aberrations
in a mouse model of CLL are among the earliest detectable modifi-
cations (Chen et al, 2009), and the loss of tumor suppression in
13q14.3 involves transcriptional deregulation by an epimutation
(Mertens et al, 2006). Genome-wide DNA hypomethylation was
already early recognized in CLL cells (Wahlfors et al, 1992; Lyko et al,
2004), and more recently, a strong correlation with transcriptional
activity was observed (Kulis et al, 2015). The DNA methylation status
is a surrogate marker for CLL patient subgroups that overexpress the
ZAP70 kinase and the mutational status of the BCR-immunoglobulin
genes that allow prognostic dichotomization of CLL into more or less
aggressive cases (Cahill et al, 2013; Claus et al, 2014). The epigenetic
subtypes of CLL defined by the DNA methylome may become impor-
tant for patient stratification as they are of prognostic relevance
(Queiros et al, 2015). These epigenetic subtypes are correlated with
the two genetically defined subgroups of CLL that express a non-
mutated or mutated immunoglobulin heavy-chain variable region gene
(IGHV) and reflect the tumor cell of origin in an epigenetic continuum
of B-cell development (Kulis et al, 2015; Oakes et al, 2016).
Here, we conducted a comprehensive characterization of the
chromatin landscape in primary CLL cells. Our analysis revealed
that the massive changes in the CLL-specific transcriptome can be
linked to deregulated chromatin features and activity changes of a
transcription factor (TF) network downstream of microenvironmen-
tal signaling cascades. Our comprehensive data set represents a rich
resource for studying gene regulation and epigenomics in CLL. We
exploited it to integrate chromatin features and TF binding with
gene expression programs in CLL B cells and suggest molecular
mechanisms for the aberrant survival of malignant CLL cells.
Results
Aberrant chromatin features identified in CLL
In order to characterize CLL chromatin modifications in correlation
with transcriptional activity, we analyzed the chromatin landscape
and the transcriptome of CD19+ B cells from peripheral blood from
23 CLL patients and from 17 pools of non-malignant B cells (NBCs)
of healthy donors (Figs 1 and EV1, Appendix Fig S1 and Table S1,
Datasets EV1 and EV2). While a number of pathophysiological
processes such as microenvironmental signaling occur in secondary
lymphoid organs of CLL patients (Burger & Gribben, 2014), the
comprehensive analysis of different epigenetic layers required the
acquisition of sufficient numbers of CD19+ B cells and was there-
fore conducted from peripheral blood. CLL patients were selected to
assess the fundamental changes in the original, untreated, and non-
evolved disease including both disease subtypes of IGHV mutated
and non-mutated samples. NBC pools were from age-matched
healthy donors. Based on the genome-wide DNA methylation pro-
files, CLL samples could be assigned to B-cell maturation stages as
shown previously (Kulis et al, 2015; Oakes et al, 2016; Fig EV1A).
These developmental changes of epigenetic signals were excluded
here for the identification of differentially methylated regions
(DMRs) between CLL cells and NBCs.
The different chromatin features we mapped are depicted at
the transcription factor 4 (TCF4) locus as an example for a gene
upregulated in CLL (Fig 1A). The readouts include DNA methylation
by whole-genome bisulfite sequencing (WGBS), histone chro-
matin immunoprecipitation (ChIP-seq) of H3K4me1, H3K4me3,
H3K9me3, H3K9ac, H3K27me3, H3K27ac, and H3K36me3, nucleo-
some occupancy from high-coverage MNase digestion followed by
H3 ChIP-seq, and open chromatin sites identified by the assay for
transposase-accessible chromatin (ATAC-seq). For selected samples,
also ChIP-seq of EBF1 and CTCF was performed. In addition, RNA
transcription was analyzed by strand-specific RNA-seq of long and
short RNAs (Appendix Fig S1A). The added value of this compre-
hensive analysis is apparent from inspection of the TCF4 gene. The
histone modifications predict downstream enhancers and intronic
enhancers that become activated in CLL cells as judged from the
enrichment of H3K4me1 and H3K27ac (Fig 1A). The predicted
enhancer loci in this region were particularly extended (> 10 kb)
and are therefore an example for so-called “super-enhancers” (SEs,
see below; Whyte et al, 2013). In order to systematically evaluate
histone modification changes, we annotated chromatin with a
12-state ChromHMM Hidden Markov model (Fig 1B). Chromatin
states differed substantially between CLL samples and NBCs and
showed transitions for repressive chromatin states 4, 5, and 6
(H3K9me3, H3K27me3) and potential enhancer states 1, 8, 9, and
11 (carrying H3K27ac and/or H3K4me1 while lacking H3K4me3;
Fig 1B and C, Datasets EV4, EV6–EV7).
To link changes of chromatin features with TF binding, we iden-
tified accessible chromatin with ATAC-seq. The method detects TF
binding by mapping open and bona fide active chromatin regions
that are depleted of nucleosomes. The differentially accessible
regions in CLL patients and NBCs comprised 38,072 loci of which
~ 24,400 loci were located at the transcription start site (TSS),
regions of transcription, and active or repressed regions (Figs 1D
and EV1E). Loss of ATAC signal in repressed regions points to a
more heterochromatic conformation in CLL, while at active chro-
matin regions, it might indicate a reduced promoter/enhancer activ-
ity. The IGHV mutated vs. non-mutated CLL can be distinguished
according to the ATAC-seq profiles (Rendeiro et al, 2016). However,
only ~ 1% of the differential ATAC-seq peaks identified here
between CLL and NBCs were related to the heterogeneity of IGHV
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mutated and non-mutated IGHV CLL samples. This finding is illus-
trated for the EBF1 TF locus in Fig EV1F.
The changes of the chromatin landscape were linked to the
deregulated activity of TFs and chromatin modifiers in CLL accord-
ing to the workflow depicted in Appendix Fig S1B. A B-cell-specific
gene regulatory network (GRN) was constructed with the ARACNE
framework (Alvarez et al, 2016). The GRN served as the backbone
to integrate TFs and deregulated epigenetic signaling and comprised
2,804 regulators with a median value of 45 target genes. It was also
used to compute the activity of TFs and chromatin modifiers from
their target gene expression with our RNA-seq data. In total, 1,378
regulators displayed a differential activity between the CLL and NBC
states (P < 0.05). As an example, TCF4 and selected deregulated
target genes are shown in Fig 1E.
Large repressive partially DNA methylated domains
When comparing DNA methylation in CLL with NBC controls, we
found a global hypomethylation in CLL as previously reported
(Wahlfors et al, 1992; Lyko et al, 2004; Kulis et al, 2012). It was
predominantly due to the formation of large partially methylated
domains (PMDs; Figs 2A and EV2A, Appendix Fig S2A–D, Dataset
EV3). Remarkably, the CLL DNA methylome contained a strikingly
large genome fraction of ~ 50% PMDs in comparison with NBCs
(< 1%; Fig 2A) with a significant overlap to PMDs previously identi-
fied for other tissues and cancer entities (Fig EV2B). The inter- and
intra-sample variability of DNA methylation in CLL cells compared
to NBC controls was high (P = 0.005, Wilcoxon rank-sum test,
Appendix Fig S2C) and CLL cells harbored an increased fraction of
intermediate DNA methylation within PMDs (P = 1.6E-4, Wilcoxon
rank-sum test, Appendix Fig S2C). PMDs were enriched for lowly
expressed and downregulated genes (Fig 2B, P = 2E-48, Fisher’s
exact test, Fig 2C), which can be rationalized by increased levels of
repressive H3K9me3 and H3K27me3 histone marks (Fig 2D and
Appendix Fig S2E). Regions with reduced transcriptional activity
like the “B compartment” determined by Hi-C chromosome
conformation capture (Fortin & Hansen, 2015) as well as lamina-
associated domains (Guelen et al, 2008) were overrepresented in
PMDs (Fig EV2C). In addition, active states (Appendix Fig S2F) and
the H3K36me3 active transcription mark (Fig 2D) were depleted in
PMDs, which were flanked by open chromatin (Fig EV2D). Our
CTCF ChIP-seq data revealed an enrichment of CTCF binding at
PMD boundaries, pointing to a potential function of CTCF to demar-
cate these regions and possibly limiting their further expansion
(Fig 2D). Of note, the majority (75%) of somatic mutations in CLLs
were located in the PMDs identified here (Fig 2E), consistent with
the increased mutation rates in heterochromatin regions (Schuster-
Bockler & Lehner, 2012). On the level of local meC changes, we
identified 8,671 differentially methylated regions (DMRs) of which
8,669 were hypomethylated in CLL (Fig EV2E). In total, 7,932 DMRs
(91%) overlapped in CLL with predicted enhancer chromatin states
(1, 8, 9, and 11; Appendix Fig S2G). Open chromatin regions within
these DMRs as detected by ATAC-seq were enriched in binding
motifs for NFATC1, EGR, and E2A (Fig EV2F).
Global changes in the promoter-associated H3K4me3
histone mark
Next, we investigated changes at promoters. When calculating
correlation functions using raw mapped reads for H3K4me3, a small
but significant extension of this signal by two additional modified
nucleosomes was detected (~ 400 base pairs, P < 0.002, Figs 3A
and B, and EV3A). We then extracted all extended H3K4me3 regions
from peak calls with a P-value < 0.05 and a median change of
400 bp. This yielded 2,785 regions for CLL and only two regions for
NBCs (Dataset EV5). The 2,785 CLL-specific extended regions
spanned over annotated TSSs (Fig EV3A). We evaluated nucleosome
occupancy using histone H3 maps obtained by MNase-ChIP-seq
(Fig EV3B) and detected a significant gain of nucleosomes at 2,639
out of the 2,785 promoters (Figs 3C and EV3C, Dataset EV5). This
change was accompanied by a loss of ATAC-seq signal in these
regions (Fig 3D). A TF binding motif analysis yielded an enrichment
for the bifunctional NFY regulator (Ceribelli et al, 2008), SP1 and
ETS and KLF family motifs when using all unchanged H3K4me3
regions as background (Fig 3E). We thus conclude that extension of
the H3K4me3 signal was linked to a gain of nucleosomes, which
might also result in the masking of TF binding sites. Genes with an
increased nucleosome occupancy around their TSS were found to be
enriched for the BCR signaling pathway, such as NFKB1 (Fig EV3C
and D). From those 23 genes in the BCR signaling pathway, 18
(80%) were downregulated in CLL.
Using the active TSS state from our ChromHMM model, alterna-
tive TSSs were extracted that were specific for CLL. In total, 49 sites
with alternative TSSs could be found that were independent of the
extended H3K4me3 signal described above, e.g., from the PITPNM2
gene (Appendix Fig S3A). In order to explore potential mechanisms
of the CLL-specific activation of alternative promoters, we searched
for enrichment of TF motifs compared to the promoter that was also
◀ Figure 1. Chromatin feature annotation, open regions, and gene regulation.A Chromatin features mapped here displayed differences between CLL patients and NBCs from healthy donors. As an example, the TCF4 locus is shown for CLL1 and
NBC donor H7 samples. The TCF4 gene encodes for a transcription factor from the E protein family. Based on the increased H3K4me1, H3K27ac, and ATAC signal, two
predicted enhancer loci were marked that became active in CLL. Note that the y-axis for RNA-seq is scaled differently for CLL (8,000) and NBCs (100) to visualize that
the TCF4 gene was not completely silenced but lowly expressed also in NBCs as evident also from the H3K36me3 mark. Light gray depicts active chromatin region
and dark gray the confined enhancer locus coinciding with an open chromatin region. The chromatin state annotation is described in panel (B).
B Chromatin segmentation of co-occurring histone modifications by ChromHMM yielding a model with 12 chromatin states. The indicated emission parameters for the
contributions of individual histone marks and the average amount of each state (Mb) for CLL and NBC samples are given.
C Chord diagram representation of genome-wide chromatin state changes between CLL and NBC. The amount of chromatin change is proportional to the size of the
segments with each tick representing 4 Mb of chromatin. Color coding of chromatin states as in panel (B).
D Distribution of ~ 24,400 annotated differentially accessible regions (ATAC-seq) in CLL compared to NBC samples (“CLL diff.”) according to the chromatin state
annotation. In total, 7,605 regions gained an ATAC-seq signal in CLL, while it was lost at 16,790 loci.
E Part of the computed B-cell gene regulatory network showing TCF4 and its deregulated target genes as well as some of the adjacent nodes. The GRN was used to
calculate the activity of regulators like TCF4 based on their target gene expression. Color code: TFs, red; target genes, gray; chromatin modifier, blue.
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Figure 2. Large partially methylated domains identified in CLL.
A Left, example of a large PMD on chromosome 2 derived from a consensus of CLL samples (n = 11). Right, genome-wide quantification of PMDs across CLL samples
(n = 11) and NBCs (n = 6). The PMDs mapped with this set of 11 CLL samples were used for further analysis in figure panels (A–E) in combination with the RNA-seq
and ChIP-seq analysis of the samples listed in Appendix Figure S1A. Red, methylated DNA; blue, unmethylated DNA.
B Expression of genes located inside (blue) and outside (gray) the PMD regions. In the boxplot, maximum, third quartile, median, first quartile and minimum are
indicated.
C Fraction of differentially expressed genes inside or outside PMD regions. Up- and downregulated genes are shown in red and green, respectively.
D Upper panel: Average signal of histone modification marks normalized to H3 and standard deviation in 5-kb windows around the  50 kb flanking regions of PMD
boundaries. Normalized fold changes were calculated by dividing to the average signal flanking outside the PMD boundaries. Blue box, within PMDs; thin line,
outside PMDs, norm.—normalized. Lower panel: Distribution of bound CTCF sites in CLL cells as determined by ChIP-seq (blue line) around the  50 kb flanking
regions of PMD boundaries in 5-kb windows. The height of the curves gives the sum of the next nearest CTCF peak at the given distance to the PMD boundary.
E Percentage of somatic mutations located inside (blue) or outside (gray) the PMD regions. Red line represents the expected ratio based on the genomic length of PMD
and non-PMD regions. Mutation data were from Puente et al (2015).
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active in NBC samples. The top four TFs identified at 67% of the
CLL-specific alternative promoters were the lineage-associated TFs
FOXA1, LEF1, POU3F1, and REPIN1 (Appendix Fig S3B).
An additional deregulated feature of the active H3K4me3 mark
was linked to the repressive H3K27me3 modification. About 4,000
promoters that were bivalent in NBCs (simultaneous presence
of H3K4me3 and H3K27me3) lost H3K4me3 in CLL (Fig 3F,
ChromHMM state 7). Many of these genes were members of the
HOX, FOX, SOX, and POU TF families that are functionally
connected with developmental processes. No differential loss of
H3K4me3 at bivalent promoters between IGVH mutated and unmu-
tated CLL was detected (Fig EV3E). Only ~ 400 promoters were
bivalent in CLL but not in NBCs (P < 0.001). Differences in apparent
promoter bivalency could also result from a heterogeneity of the
individual marks. However, a truly bivalent state with H3K4me3
and H3K27me3 has only very low levels of transcription (Voigt
et al, 2013). In contrast, a mixture of cells with fully active promot-
ers (H3K4me3) and cells with silenced (H3K27me3) promoters
should display transcriptional activity from the H3K4me3 fraction.
For our set of promoters, we found that 67% of bivalent promoters
were silent in NBCs (RPKM < 0.1) and thus represent bona fide
bivalent promoters. We therefore propose that a large fraction of
bivalent promoters that were poised for activation changed into a
repressed state in CLL cells and retained only the H3K27me3 mark.
In ~ 1,700 CLL promoters that lost H3K4me3, binding motifs of the
MEF2 family of transcriptional activators were enriched (Fig 3G).
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Figure 3. H3K4me3 and nucleosome positioning changes at promoters.
A Correlation function of H3K4me3 ChIP-seq reads. A broadening of H3K4me3 domains in CLL by 1–2 nucleosomes was detected. The number of replicates analyzed
was 11 (CLL) and 4 (NBC), respectively. Error bars represent the SEM.
B H3K4me3 peak width distribution at common promoters in CLL and NBC controls. In the boxplot, maximum, third quartile, median, first quartile and minimum are
indicated. The number of replicates analyzed was 11 (CLL) and 4 (NBC), respectively.
C Distribution of nucleosome occupancy calculated from histone H3 ChIP-seq averaged over a 1,000-bp window within promoters. H3K4me3 regions displayed higher
nucleosome density for CLL as compared to NBC samples. The boxplot representation and number of samples was the same as in panel (B).
D Exemplary region at the TAF13 promoter showing higher H3K4me3 levels upstream of the TSS with lost ATAC signal (gray bar) as compared to the NBC control.
E TF motif analysis of ATAC signal lost at CLL promoters with broadened H3K4me3 regions.
F Heatmap of genome-wide histone modification patterns at promoters within 2 to 5 kb around the TSS (x-axis) for an NBC (H3) and a patient (CLL1) sample. Each
line on the y-axis corresponds to one promoter. The clustering revealed one cluster with loss of H3K4me3 at bivalent promoters in CLL.
G TF motif analysis at bivalent promoters that lost H3K4me3 in CLL.
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The MEF2 family TFs were suggested to regulate H3K4me3 (Pon &
Marra, 2016; Di Giorgio et al, 2017) also in the context of
H3K27me3 (Aziz et al, 2010). Furthermore, the H3K4-specific
methylases KMT2B (MLL2) and KMT2D (MLL4), and to a lesser
degree also KMT2A/C/E, were downregulated in CLL (Fig EV3F).
Accordingly, we speculate that both the reduced activity of KMT2
enzymes and their impaired targeting by MEF2 TFs contribute to
the loss of H3K4me3 at bivalent promoters in CLL.
Annotation of potential enhancers
The active ChromHMM states 1, 8, 9, and 11 comprised 238,820
regions (368 Mb) and represent loci that potentially contain enhan-
cers. This set overlapped with the corresponding B- and T-cell chro-
matin states of the Roadmap consortium to 89.8 and 72.2%,
respectively (Fig EV4A, Dataset EV9). The majority of previously
reported enhancer loci from ENCODE and FANTOM projects were
found in our state “Active 2” (state 9, H3K4me1, H3K27ac) and with
a lower enrichment in states 1, 8,10, and 11 with the bivalent chro-
matin state 7 being the most enriched repressive state (Fig EV4B and
C). Furthermore, binding sites of MEF2, IRF4, and FOXM1 identified
by ENCODE were enriched in these states (Fig EV4B). The most
prominent chromatin state transitions from NBCs to CLL cells were
from “Quiescent” (state 12) to “Poised” (state 8, H3K4me1), from
“Transcribed” (state 2, H3K36me3 in the body of transcribed genes)
to “Active 3” (state 1, H3K4me1, H3K27ac, and H3K36me3, predic-
tive for active intragenic enhancers) and from “Poised” to “Active 2”
(state 9, H3K4me1 and H3K27ac, predictive of intergenic enhancers;
Fig 4A and B). Genome-wide, the highest overlap with bidirectional
expression of RNA was observed with “Active 1” (state 10, predictive
for TSS) and “Active 2” (state 9, predictive for active intergenic
enhancer; Fig 4A and C). Bidirectional RNA expression at enhancers
could also discriminate between CLL and NBCs, identifying a set of
disease-specific active enhancers (Fig 4D).
Next, super-enhancers were annotated by clusters of open chro-
matin regions co-occurring with large regions of H3K27ac domains
in the range of 10 kb and above by using the ROSE software tool
(Whyte et al, 2013; Dataset EV9). In total, 310 out of a union set of
1,289 SEs showed differential activity (false discovery rate
(FDR) < 0.01). There were 219 up- and 91 downregulated SEs in
CLL as compared to NBCs (Fig 4E). Exemplary predicted SEs that
became active and upregulated the associated genes in CLL are
shown for TCF4, CREB3L2, and FMOD (Figs 1A, and EV4D and E).
The CLL-relevant genes that were up-/downregulated by proximal
SEs are depicted in Fig 4E and F. The list includes the T-cell recep-
tor alpha locus on chromosome 14 (TRA locus), the immune check-
point receptor CTLA4, FMOD as a CLL tumor-associated antigen
allowing for expansion of specific CD8+ autologous T lymphocytes
(Mayr et al, 2005), and BCL2, a highly successful therapeutic target
(Kipps et al, 2017). For the latter, a SE-mediated regulation has
been detected previously in non-Hodgkin lymphoma and CLL
tissue (Meng et al, 2014). Interestingly, SE activity nearby the
cyclin-dependent kinase inhibitor 1 gene CDKN1A (encoding p21)
was reduced in CLL, which has been reported to be a p53-indepen-
dent tumor suppressor (Abbas & Dutta, 2009). In addition, we
found a number of TF genes being activated by proximal SEs in
CLL that include LEF1, ETV6, and NFATC1 in addition to TCF4 and
CREB3L2 mentioned above.
Impact of histone deacetylase inhibition on enhancer and
promoter activities
On a genome-wide scale, a large number of transitions from active
chromatin states in CLL involved a loss of the H3K27ac modification
(Fig 1D). Accordingly, we examined whether histone deacetylase
(HDAC) activity differed between CLL and NBCs. A significant
upregulation of several members from all HDAC classes (HDAC1,
HDAC3, HDAC8, HDAC9, SIRT5) on the RNA level was apparent in
CLL (Fig 4G). Direct measurements of the global activity of class I/II
HDACs revealed an about fourfold higher activity in primary CLL
cells compared to NBCs (Fig 4H). This activity could be efficiently
inhibited with panobinostat. Upon treatment of primary B cells from
▸Figure 4. Differential enhancer activity in CLL and NBCs.A Overlap of active regions identified in CLL and NBCs by ChromHMM, ATAC peaks, or bidirectionally expressed RNA loci labeled as “Bidi”. Venn diagram showing the
total number of overlapping regions (not area-proportional).
B Chromatin transitions within differential active states between NBC and CLL. Heatmap representation of the amount of chromatin (log2Mb + 1) transitioning from a
particular state in NBC (rows) to CLL (columns). Transitions were considered for all recurrent active chromatin state regions (states 1, 8, 9, and 11) present in a minimum
of three samples even if the consensus state was not an active state. Accordingly, the matrix includes transitions between non-active states at low frequencies.
C Chromatin states at bidirectionally transcribed predicted enhancers loci. All Bidi loci identified in NBC samples (n = 961) and CLL samples (n = 8,530) are shown. The
Bidi loci show an enrichment of the states “Active 2 (predicted active enhancer)” and “Active 1 (predicted transcription start sites)”.
D Clustering of samples via expression of bidirectionally regions that are differential between NBCs and CLL and quantified using DESeq2.
E Volcano plot of differential super-enhancers targeting known leukemia and cancer genes. Examples include SE loss at CDKN1A, PI3KC2B, and KMT2B (MLL2) and SE
gain at FMOD, CREB3L2, CTLA4, TCF4, LEF1, and BCL2. Points represent non-differential SEs (gray) and differential SEs (FDR < 0.01) with fold change > 1 (orange).
F RNA expression changes of selected genes associated with differential SEs. Top: genes significantly (FDR < 0.05) upregulated by SEs in CLL. Bottom: genes significantly
downregulated by SEs in CLL. In the boxplot, maximum, third quartile, median, first quartile and minimum are indicated. The number of replicates analyzed was 19
(CLL) and 7 (NBC), respectively.
G Comparison of normalized gene expression of histone deacetylases between CLL and NBCs. Histone deacetylases significantly upregulated in CLL are shown in bold.
The boxplot representation and number of samples was the same as in panel (F).
H HDAC activity and its inhibition by panobinostat in B cells from CLL patients (red) in comparison with healthy donors (gray). Error bars indicate standard deviation
measured in four biological replicates.
I Genome browser view of H3K27ac tracks (in gray) at exemplary genes for NBCs and CLL cells 24 h after mock and after panobinostat treatment. At genes such as
CDKN1A (cell cycle control) and KLF13, reduced H3K27ac signal in CLL was increased upon HDAC inhibition to the level found in NBCs. WNT11 is shown as an example
of a de novo gain of an active enhancer due to treatment with panobinostat.
J Heatmap displaying changes in H3K27ac read occupancy in CLL upon panobinostat treatment for 24 h. A general gain of H3K27ac in enhancers upon panobinostat
treatment was observed.
ª 2019 The Authors Molecular Systems Biology 15: e8339 | 2019 7 of 20
Jan-Philipp Mallm et al Molecular Systems Biology
Published online: May 22, 2019 
NBC
n=961
CLL
n=8530
-1
 k
b
+1
 k
b
-1
 k
b
+1
 k
b
1
2
3
4
5
6
7
8
9
10
11
12
Chromatin
state
Act3
Tx
HetZNF
Het
Repr2
ReprPC
Biv
Pois
Act2
Act1
Act4
Quies
H
A Potential active enhancer containing loci(ChromHMM 1, 9, 77863 loci)
Bidi CLL
(373)
Bidi NBC
(168)
ATAC CLL
(10145)
ATAC NBC
(7312)
14 8
5279
4462
2511
21
14
27
77 4 2 1
57
55 197
B
S
ta
te
 in
 N
B
C
Tx
Biv
Act3
HetZNF
Het
Repr
ReprPC
Pois
Act2
Act1
Act4
Quies
State in CLL
A
ct
3
Tx
H
et
ZN
F
H
et
R
ep
r
R
ep
rP
C
B
iv
P
oi
s
A
ct
2
A
ct
1
A
ct
4
Q
ui
es
Enhancer state transitions
0 4 (log2 Mb+1)
G
0
10
20
30
40
R
N
A-
se
q 
(R
PK
M
)
NBC
CLL
HDAC class I HDAC class II Sirtuins
HD
AC
1
HD
AC
2
HD
AC
3
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
6
HD
AC
9
HD
AC
7
HD
AC
10
HD
AC
11
SI
RT
1
SI
RT
2
SI
RT
3
SI
RT
4
SI
RT
5
SI
RT
6
SI
RT
7
WNT11
H
3K
27
ac NBC
CLL contol
CLL+PS 24h
KLF13
H
3K
27
ac NBC
CLL control
CLL+PS 24h
2000
2000
2000
CDKN1A
H
3K
27
ac NBC
CLL control
CLL+PS 24h
2000
2000
2000
2000
2000
2000
CLL
NBC
Panobinostat (nM)
H
D
A
C
 I/
II 
ac
tiv
ity
 (a
. u
.)
10
20
30
40
0 0.025 0.25 2.5 25 250
I
C
LL
13
C
LL
12
C
LL
14
C
LL
12
C
LL
13
C
LL
14
H3K27ac
low high
Control PS 24 h
Enh.
Prom.
Other
J
D E
R
N
A
-s
eq
 (R
P
K
M
)
0
50
100
150
200
0
50
100
150
BCL2 CREB3L2 FMOD NOSIP
DENND3 RHBDF2 IQSEC1 PIK3C2B
NBC
CLL
F
Fold change (CLL vs NBC)
−l
og
10
 (F
D
R
)
NOSIP
TRA−locus
CTLA4CD5
RASGRF1
TCF4
FMOD
GRB2
RHOF
CDK14
LEF1
CREB3L2
EHMT1
GDF7
ARID3A
BCL2
RASSF2
KDM2B
ETV6
PIK3C2B
NFKBIE
BAZ1A
NFATC1
CDKN1A
DENND3
TGFBR3
0
10
20
30
40
−3 0 3 6
Differential Bidi regions 
NBC CLL
C
Figure 4.
8 of 20 Molecular Systems Biology 15: e8339 | 2019 ª 2019 The Authors
Molecular Systems Biology Jan-Philipp Mallm et al
Published online: May 22, 2019 
CLL patients and healthy donors in vitro for 2 and 24 h according to
the scheme depicted in Appendix Fig S4A, H3K9ac and H3K27ac
acetylation levels increased as expected (Appendix Fig S4B). The
panobinostat treatment was substantially more toxic to CLL cells
than to NBCs (Appendix Fig S4C and D) and induced changes of
gene expression and histone modifications (Fig 4I and J,
Appendix Fig S4E). Deregulated H3K27ac patterns could be reverted
in part by treatment with the HDAC inhibitor panobinostat and
affected both promoters and enhancers (Fig 4J). Gene expression
levels of 17% of all nascent transcripts were significantly up- or
downregulated (Appendix Fig S4E). After 2 h of panobinostat treat-
ment, only chromatin modifying processes were affected (e.g.,
upregulation of histone acetylation). At the 24-h time point, tran-
scription of genes changed that were associated with RNA metabo-
lism, possibly compensating the HDAC inhibition-related gene
expression changes. Notably, a number of genes involved in BCR
signaling and apoptosis were affected. These changes included reac-
tivation of BCL2L11, CDKN1A, PIK3CB1, NFKBIA, MEF2C, and IRF3
in CLL, while BCL2, ZAP70, LEF1, ETS1, and RUNX1 were repressed
(Dataset EV11). The complex gene expression response after
panobinostat treatment can be rationalized by considering that pan-
HDAC inhibitors like panobinostat not only induce histone hyper-
acetylation, but also affect posttranslational acetylation of non-
histone proteins including TFs. For example, it has been shown that
acetylation changes the activity of NF-jB (Chen et al, 2001),
enhances DNA binding and transactivation of MEF2C (Ma et al,
2005), and decreases DNA binding and transcription activity of SP1/
3 (Braun et al, 2001; Waby et al, 2010).
Differential occupancy of TF binding sites at enhancers
We identified TF binding motifs in ATAC-seq peak regions (median
size 327 bp) for different potential enhancer loci and excluded a
 1 kb region around promoters. The annotations included differen-
tial ATAC signals (Dataset EV10) at ChromHMM states 1, 8, 9, and
11 (Fig 5A and C), states 1 and 9, which both carry a strong
H3K27ac signal (Appendix Fig S5A), and states 8 and 11 for poten-
tial poised or weak enhancers (Appendix Fig S5B). In addition, the
consensus ATAC peaks were intersected with DMRs for states 1, 8,
9, and 11 (Fig EV2F) as well as differential H3K27ac regions either
genome-wide (excluding promoters; Appendix Fig S5C) or for SEs
called as described above (Appendix Fig S5D). These different
approaches showed a large overlap of the TF motifs retrieved.
Motifs recognized by E protein (including TCF4), TCF7/LEF, NFAT,
EGR, and Forkhead TF families were gained in CLL, while motifs
that were lost in CLL were mostly from the EBF, ETS, NF-jB, and
JUN/FOS (AP-1) families (Appendix Table S2). PAX5, which has
been recently identified within CLL subgroups as an essential super-
enhancer factor for CLL cell survival (Ott et al, 2018), was no top
hit in our differential TF motif analysis of SEs in CLL vs. NBCs. For
the largest set of potential enhancer loci (ChromHMM states 1, 8, 9,
11), NFAT and E2A (E protein family) motifs were identified for
sites that gained ATAC signal in CLL (Fig 5A). In addition, a total of
279 potential enhancer loci simultaneously exhibited significant
changes of their H3K27ac signal at DMRs. For 256 (92%) of these
sites, H3K27ac increased while meC was lost, suggesting that meC
loss was correlated with enhancer activation. As an example, NFAT
binding motifs are displayed, which revealed both a decrease in
DNA methylation and an enrichment of the H3K27ac mark in CLL
cells (Fig 5B). This finding points toward activation of this TF in
CLL cells as shown previously (Oakes et al, 2016) in dependence of
DNA methylation and H3K27ac. Next, we performed a correspond-
ing TF motif analysis within regions with lost ATAC-seq signal in
CLL at predicted enhancer loci (ChromHMM states 1, 8, 9, 11). The
most frequently lost motifs were those of EBF/EBF1 and CTCF
(Fig 5C). The differential gain or loss of binding of selected TFs was
further analyzed by ATAC-seq footprinting at the genomic location
of the motif sequences from Fig 5A and C as shown for E2A, EBF,
and CTCF (Fig 5D). While the fine-scale pattern also reflected the
sequence preference of the Tn5 transposase, the depth of the
footprint and the differential accessibility around the aligned motifs
confirmed the gain/loss of occupancy in CLL precisely at the target
sequence.
The differential CTCF occupancy as inferred from ATAC-seq was
corroborated by a CTCF ChIP-seq analysis and revealed clear dif-
ferences between CLL cells and NBCs (Fig EV5A). Using DiffBind to
extract differentially occupied regions from our CTCF ChIP-seq data,
we found that CTCF binding was lost in CLL cells at 5,964 sites and
gained at 441 sites (Fig EV5B). Of these lost sites, 93% overlapped
with peaks from the ENCODE data set of the B-lymphocyte cell line
GM12875 (GEO GSM749670), and with 55 and 47% of the gained
and lost CTCF sites, respectively, determined from our ATAC-seq
analysis. CTCF was lost in CLL cells mostly at chromatin states
predictive for enhancers (Fig EV5C). In addition, while CTCF
▸Figure 5. ATAC-seq and TF binding motif analysis of enhancers.A Plot of the most enriched TF binding motifs in regions that showed gained ATAC-seq signal at ChromHMM states 1, 8, 9, and 11 (predictive for enhancers). Color
coding represents different TF classes. The size of the spots is proportional to the percentage of target sequences with a given motif.
B H3K27ac (left) and DNA methylation (right) at NFAT binding sites. CLL cells showed both an H3K27ac enrichment and DNA hypomethylation at NFAT target sites,
suggesting a higher activity of TFs from the NFAT family in CLL.
C Same as panel (A) but for lost ATAC-seq signal.
D ATAC footprints for E2A, EBF, and CTCF motifs from the Homer analysis. The E2A motif footprint (binding site of E protein family TFs like TCF4) displayed an increased
binding signal in CLL, while sites with the EBF and CTCF motif lost the ATAC signal.
E Expression of the genes nearest to target enhancers with constitutively bound (“stable”) CTCF vs. enhancers that lost CTCF in CLL. Loss of CTCF binding correlated
with reduced gene expression.
F Correlation matrix of simultaneously open regions computed from the scATAC-seq data. For all loci, the pair-wise correlation coefficients were calculated and plotted
to visualize how different loci were wired to each other. As an example, the TCF4 locus on chromosome 1 is depicted.
G Enhancer–promoter rewiring at the NFKB2 locus. Top: Clustering of NBC and CLL samples according to gene expression of NFKB2, PSD and FBXL15. NBC samples were
in the left cluster with high NFKB2 expression, which was reduced in the right cluster containing the CLL samples. Bottom: A switch of interactions between the
NFKB2 promoter and two different enhancers in CLL (red line) vs. NBCs (gray line) was observed. Based on the CTCF ChIP-seq analysis, both intronic enhancers at the
NFKB2 and the FBXL15 gene show constitutively bound CTCF nearby, even though the targets of the two enhancers were switched.
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demarcated PMDs as shown above, the PMD boundaries did not
colocalize with TAD boundaries (Fig EV5D). Furthermore, loss of
CTCF did not occur at TAD boundaries, which were rather occupied
by CTCF in both malignant cells and NBCs (Fig EV5E). However,
loss of CTCF was linked to the downregulation of the nearest gene
in CLL (Fig 5E).
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For the further analysis, we compiled lists of “active enhancers
in CLL” and “active enhancers in NBCs”. They were derived from
the consensus of individual ATAC-seq peak regions flanked by
active chromatin states 1 and 9 (Dataset EV9). The two lists
comprised 10,145 loci in CLL and 7,312 in NBCs of which 4,771
were shared between the two groups after merging. The enhancers
defined in this manner showed a large overlap of 85  8% (average
and standard deviation for all patient samples) with those identified
from a corresponding analysis based on ATAC-seq peaks flanked by
H3K27ac peaks instead of using the ChromHMM states. This finding
is to be expected since states 1 and 9 carry a strong H3K27ac signal
that is obtained from the peak called H3K27ac ChIP-seq used as
input for ChromHMM.
Mapping promoter–enhancer interactions from single-cell
ATAC-seq data
Next, we identified accessible chromatin loci in single cells via
single-cell ATAC-seq (scATAC-seq), which can resolve the hetero-
geneity between individual cells (Appendix Fig S6A–C). We
analyzed 494 malignant cells from three CLL patients and 343 NBCs
from two healthy donors. Distinct signatures of co-occurring open
loci were found across different cells with a high overall overlap of
open chromatin regions identified by bulk ATAC-seq and scATAC-
seq. The heterogeneity of TF binding between single cells was
assessed from the integration frequency of ATAC at known TF bind-
ing motifs (Appendix Fig S6B). Several motifs like NRF1, NFYA/B,
and JUN/FOS (AP-1) identified above from the analysis of deregu-
lated CLL chromatin features at promoters and enhancers displayed
also the highest heterogeneous accessibility between individual cells
in CLL.
Single-cell ATAC-seq can also reveal co-regulation of genomic
loci by correlating concomitant accessibility of loci in heterogeneous
cell populations. Based on the scATAC-seq data, we computed
correlation matrices that contain information about pairs of genomic
regions that are simultaneously open in the same cell (Fig 5F).
Correlations between two regions can arise from spatial contacts
between them or from other types of co-regulation, e.g., binding of
a common regulator to both loci in the same cell. Using the anno-
tated “active enhancers in CLL/NBC” lists (Dataset EV9), about 800
accessible enhancers per cell were detected on an average. With a
threshold derived from the correlation coefficients obtained in a
permuted data set (Appendix Fig S6D and F), we then identified
enhancer–promoter pairs within 100-kb windows (Dataset EV10).
We found that 68% of these pairs were also listed as spatial contacts
in the 4D genome database (Teng et al, 2015), suggesting that 2/3
of the promoter–enhancer pairs involve physical contacts. In total,
3,955 promoter–enhancer pairs were identified, with most promot-
ers being connected to one enhancer at mean and median distances
of 32 and 20 kb (CLL) and 23 and 10 kb (NBCs), respectively
(Appendix Fig S6E and G). A total of 1,612 pairs were specific for
CLL, 1,932 pairs were specific for NBCs, and 411 pairs were present
in both CLL and NBCs. In addition, a set of 205 rewired promoters
was defined as promoters that do not share any enhancer between
CLL and NBCs but were correlated with at least one enhancer in
each of the cell types. Within this set of rewired promoters, 70 and
49 were linked to genes down- and upregulated in CLL, respectively.
These genes were enriched for pathways involved in signal
transduction, apoptosis, and differentiation. We then evaluated the
properties of enhancers that were assigned to different target genes
in CLL and NBCs. Based on our CTCF ChIP-seq analysis, we found
that at 90% of the rewired enhancers CTCF was stably bound in
both cell types (Fig EV5F). As an example, the NFKB2 locus that is
downregulated in CLL is shown (Fig 5G). In CLL, the regular
enhancer of NFKB2 was replaced with an enhancer that was
connected to the FXB15 gene in NBCs. The FXB15 enhancer had a
reduced activity as inferred from the loss of ATAC signal in CLL,
potentially causing downregulation of NFKB2. Based on these obser-
vations, we propose that rewiring between enhancers and their
target promoters might be one mechanism that leads to deregulated
gene expression in CLL. This process appears to be independent of
CTCF binding changes. Rather, it is consistent with the previous
conclusion that CTCF insulates larger contact domains, while speci-
fic enhancer–promoter interactions might involve other factors like
YY1 (Weintraub et al, 2017).
Assignment of TFs to aberrant CLL chromatin features
Aberrant regulatory epigenetic signals were detected at 81% of the
transcriptionally deregulated genes in CLL (Fig 6A, Datasets EV11
and EV12). Based on our TF motif analysis at promoters and enhan-
cers, we selected the most relevant TFs that displayed differential
binding with respect to two or more of our chromatin readouts as
described in Materials and Methods (Appendix Table S2). These TFs
were assigned to four different deregulated CLL chromatin features
at promoters or enhancers (Fig 6B). A gene set enrichment analysis
of targets of these TFs retrieved pathways that are highly relevant
for the CLL pathophysiology (BCR, NF-jB, and MAPK signaling;
Fig 6C, Appendix Fig S7). Relevant links in this context were, for
example, from SYK (Benkisser-Petersen et al, 2016) to NFATC1,
BCL2 (Roberts et al, 2016) to TCF4, and NOTCH1 (Fabbri et al,
2017; Ryan et al, 2017) to NF-jB. Using the connections provided
by our gene regulatory network, specific chromatin modifiers were
identified that had deregulated activities and could be involved in
the observed changes of meC, H3K4me3, H3K27me3, and H3K27ac
at promoters and enhancers (Appendix Fig S7). The resulting dereg-
ulated TF network thus rationalizes how epigenetic dysregulation in
CLL could be linked to changes in TF activity. This TF network can
be used to generate hypotheses on how these activity changes are
driven by external signaling and how the chromatin aberrations
feedback to signaling.
Integrative gene regulatory enhancer network analysis
The pair-wise correlations between enhancers and promoters
computed from the scATAC-seq data was combined with the B-cell
GRN to derive a “gene regulatory enhancer containing network”
(GREN; Datasets EV13 and EV14). From the complete GREN, a CLL-
specific GREN was extracted that includes the connected network
derived from the CLL-specific TF list, their target genes, as well as
linked chromatin modifiers that affect the aberrant chromatin
features in CLL. As an additional requirement for this selected
network part, all included factors needed to be deregulated in their
activity/expression between CLL and NBCs. A part of this network
that is centered around TCF4 and EBF1 is shown in Fig 6D. To vali-
date the ATAC-based motif analysis for EBF1 (Fig 5C) and
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predictions from our CLL GREN, we conducted a ChIP-seq analysis
of EBF1. Binding of EBF1 was lost at 826 sites and gained at 173
sites in CLL, separating malignant and NBC samples and showing a
very good overlap with the ATAC analysis (Appendix Fig S8A–D).
Interestingly, genes that in CLL lost EBF1 binding at their enhancers
could be clustered into the functional groups of immune response
and cell activation, two pathways of central relevance in the patho-
physiology of CLL (Appendix Fig S8E). We then applied our CLL-
specific GREN to dissect regulation by EBF1, which can act as both
an activator and repressor (Boller et al, 2018). Several enhancers of
EBF1 target genes were predicted to be active only in NBCs (H402,
H441, H464, H1000) and silenced in CLL. These enhancers represent
candidates for being driven by EBF1, which is lost in CLL. As an
example, H464 and its target gene SNX22 are highlighted (Fig 6D).
We confirmed the predicted loss of EBF1 at the intronic H464
enhancer by ChIP-seq and determined a global CLL-specific EBF1
binding pattern (Fig 6E, Appendix Fig S8 and Table S3). Although
H3K27ac at the SNX22 locus was only slightly reduced, transcription
of the SNX22 gene was largely decreased (average log fold changes
5.1) as evident from the RNA-seq tracks (Fig 6E). Furthermore,
enhancers H1000 (MICAL3 gene) and H441 (NIN gene) also showed
the expected loss of EBF1 binding, while little change was observed
for H402 (NIN gene, not shown; Appendix Fig S8F). Thus, for three
out of four enhancers in our CLL-specific gene regulatory network, a
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Figure 6. Integration of chromatin state changes, TF binding, and gene expression.
A Relation of chromatin states and gene expression changes. For 81% of differentially expressed genes, a change in a regulatory chromatin feature was observed.
B Scheme of chromatin feature changes and associated TFs identified in this study (Appendix Table S2).
C Pathway analysis of identified core TFs and their target genes from our B-cell GRN. Significantly enriched gene sets (P < 0.05) relevant to CLL pathophysiology were
retrieved (BCR signaling, NF-jB signaling, and MAPK signaling).
D CLL GREN. TFs identified here, associated chromatin modifiers, and differentially expressed target genes were integrated into a network. A part that includes TCF4
and EBF1 is shown. The different TSSs of the TCF4 gene (Fig 1A) were combined into a single gene target for the corresponding SE. Several enhancers of EBF1 target
genes were active in NBCs (H402, H441, H464, H1000) but became silenced in CLL. As an example, H464 and SNX22 are highlighted by a red rectangle. These
enhancers represent candidate enhancers for involving EBF1 binding. Color code: active enhancers, dark, light, and medium green for CLL only (“C”), only in NBCs
(“H”), and both cell types (“CH”), respectively; TFs, red; target genes, gray; chromatin modifier, blue.
E Analysis of regulation of SNX22 by the intronic H464 enhancer shown in panel (B). This enhancer lost its ATAC signal at the predicted EBF1 binding site. EBF1 ChIP-
seq analysis validated that EBF1 is indeed lost at this site. Although H3K27ac at the locus was only slightly reduced, transcription of SNX22 was largely reduced. These
findings are consistent with a mechanism where EBF1 binding drives gene expression of SNX22 by binding to H464.
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predicted loss of EBF1 binding in CLL was experimentally validated
by the EBF1 ChIP-seq.
Discussion
Here, we dissected the aberrant epigenetic circuitry in primary CLL
cells vs. NBCs by conducting a comprehensive analysis of chromatin
modifications. Deregulated chromatin features were uncovered that
included both localized changes at regulatory enhancer and
promoter elements as well as large-scale chromatin reorganization
on the Mb scale and above. The most striking example for the latter
was the massive accumulation of large PMDs. These domains corre-
lated with repressive chromatin and gene silencing as in other
cancers (Berman et al, 2011; Hon et al, 2012; Hovestadt et al, 2014;
Schultz et al, 2015). They mapped to lamina-associated domains
(Guelen et al, 2008) and Hi-C B compartments (Fortin & Hansen,
2015; Fig EV2C), reflecting an enhanced heterochromatic chromatin
organization in CLL. Interestingly, boundaries of PMDs were
enriched for occupied CTCF sites, which might indicate a role of
CTCF to limit the expansion of PMDs. This view is supported by the
finding that CTCF binding sites can act as bifurcation points for
differential DNA methylation and that CTCF binding can be modu-
lated by DNA demethylation activity (Teif et al, 2014; Wiehle et al,
2019). Our integrative analysis of a large set of readouts revealed
altered chromatin features at promoter/enhancer elements for 81%
of the differentially regulated genes in CLL cells (Fig 6A). The
underlying CLL-specific TF network that we derived from aberrant
chromatin features displayed strong connectivity with epigenetic
readers and writers such as SIN3 and the NuRD and SWI/SNF chro-
matin remodeling complexes that were deregulated in CLL
(Appendix Fig S7, Dataset EV14). While little is known about the
function of remodeling complexes in CLL, the NuRD and SWI/SNF
remodelers play an important role in hematopoiesis and differentia-
tion and have been implicated in oncogenesis and cancer progres-
sion in numerous other entities (Lai & Wade, 2011; Kadoch &
Crabtree, 2015; Prasad et al, 2015). Furthermore, it is noted that the
ability of these complexes to translocate nucleosomes might be
crucial to modulate chromatin accessibility at enhancers and involve
their targeting by histone modifications like H3K4me1 (Local et al,
2018). In line with these considerations, we observe striking
changes in nucleosome positioning and occupancy at B-cell-specific
genes in CLL. In our promoter analysis, changed nucleosome occu-
pancy at active promoters resulted in a loss of accessible chromatin
and additionally modified histones. This change seems somewhat
different from the broadened H3K4me3 regions observed previously
in other entities (Chen et al, 2015) as the extension observed in CLL
comprised only 1–2 nucleosomes. Interestingly, extension of the
H3K4me3 mark via gain of nucleosomes at transcriptional start sites
and loss in ATAC-seq signal was linked to an enrichment of TF
binding motifs for NFYA, SP1, and KLF proteins. This finding may
point to a loss in TF binding due to the higher nucleosome density
that also could contribute to the extension of the H3K4me3 signal. A
bivalent signature switch at CLL promoters characterized by a loss
of the active H3K4me3 mark points to a reduced developmental
plasticity of CLL cells. According to our analysis, loss of H3K4me3 is
predicted to occur via MEF2 TFs (Aziz et al, 2010; Di Giorgio et al,
2017) and reduced KMT2 activity. Furthermore, we find a number
of additional links in our core TF network to modifiers of H3K4me3
that included, for example, KMT2E, KDM5A, SETD7 (Appendix Fig
S7, Dataset EV14).
Extensive changes of enhancer activity were observed that
allowed us to clearly discriminate between CLL and NBCs, with a
pronounced loss of enhancer activity in CLL. It could be related to
an elevated HDAC activity measured in CLL samples and was
reverted in part by panobinostat treatment that led to increased
H3K27ac at enhancers. Our scATAC-seq analysis revealed correla-
tions between bona fide active sites and led us to propose that
enhancer-mediated changes of transcription activity occurred via
rewiring to different target promoters in CLL cells. A similar data set
does not exist for CLL, as only direct physical contact have been
mapped at low resolution by Hi-C (Beekman et al, 2018) or for
selected interactions by 4C (Ott et al, 2018).
From our chromatin feature maps, we derived a highly
connected CLL-specific network centered around the TFs targeting
17 central binding motifs and an enrichment of BCR signaling genes
(Fig 6B and C, Appendix Fig S7 and Table S2, Dataset EV14). These
central motifs include gained motifs in CLL for NFAT, TCF4, and
LEF1 and lost motifs for EBF1 and AP-1, which have similarly been
reported in two other studies (Oakes et al, 2016; Beekman et al,
2018). The integrated view on the interplay of TFs, chromatin modi-
fiers, and associated target genes derived here provides a rich
resource to generate hypotheses for novel molecular links to the
CLL pathophenotype. For example, the regulation of BCL2 via TCF4
predicted in our GREN (Appendix Fig S7) is of special interest since
it is the target of venetoclax, a highly effective treatment option in
CLL (Roberts et al, 2016). The importance of enhancers as drivers
of deregulated gene expression in CLL is another notable finding
emerging from our work. Since a large number of enhancers change
their activity state and/or their target genes, a promoter centric view
will be insufficient to rationalize the global reprogramming of the
CLL transcriptome. Finally, given the complex interlinked structure
between a large number of TFs, chromatin modifiers, and their
target genes, it appears quite clear that simple linear models will not
be able to fully grasp essential parts of the pathomechanism.
Accordingly, we envision that the approach of developing integrated
gene regulatory enhancer containing networks will prove to be valu-
able for therapy response prediction and patient stratification for
CLL. Furthermore, the comprehensive data sets created here and in
another study (Beekman et al, 2018) provide a rich resource for CLL
researchers. It will largely facilitate studies that involve clinically
relevant disease phenotypes with deregulated molecular mecha-
nisms, which are reflected by the multitude of aberrant features
present in the CLL epigenome.
Materials and Methods
Patient samples
All CLL patients analyzed in this study gave written informed
consent (ethics committee approval) and were characterized in
the diagnostics department of the University Hospital Ulm
(Appendix Table S1). The median age of the CLL patients was
62 years (range, 47–79). NBC control samples were enriched from
peripheral blood of in total 65 age-matched donors (median,
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57 years, range, 51–70) that were collected in 17 sample pools. For
all samples from CLL patients and from NBC donors, CD19-positive
B cells were purified, yielding a CD19-positive fraction of 98  2%
in NBC donor and 99  1% in CLL patient samples. A fraction of
79% of CLL patients had favorable genetic aberrations [del(13q)] as
sole abnormality associated with increased survival times, 21% had
normal karyotype. 61% of the patients were diagnosed with hyper-
mutated IGHV associated with good prognosis. Due to the high
numbers of B cells required for multiple sequencing, we selected
asymptomatic CLL patients who had been approached with the
watch-and-wait strategy. None of the patients analyzed had previ-
ous treatment of the CLL disease with high numbers of CLL cells
unaffected by the potential impact of prior therapy in the peripheral
blood with a median leukocyte count of 101.4 × 109/l (range, 37.5–
280.6 × 109/l).
Whole-genome bisulfite sequencing
DNA was extracted with the AllPrep DNA/RNA Mini Kit (Qiagen),
spiked with unmethylated lambda DNA (Promega) and sonicated to
achieve an average size of 250–300 bp. After bisulfite conversion
using the EZ DNA Methylation Kit (Zymo), strand-specific WGBS-
seq libraries were prepared as described previously (Kretzmer et al,
2015). For each library, three lanes with 100 bp paired-end reads
were sequenced on the Illumina HiSeq 2000 system.
ChIP-seq of histone modifications and transcription factors
Patient-derived cells were cross-linked with 1% methanol-free
formaldehyde for 10 min. After quenching with glycine, cells were
washed three times with PBS and the cell pellet was frozen in liquid
nitrogen. For analysis, the cell pellet was thawed and treated with
four units MNase per 1 × 106 cells for 15 min. MNase was stopped
with 10× covaris buffer, and the chromatin was sheared for an addi-
tional 15 min with the S2 covaris device. The soluble chromatin
was then recovered and subjected to a background-minimizing pre-
clearing step with an unspecific IgG antibody. For each ChIP assay,
an equivalent of 3 × 106 cells was used. After the IP, chromatin was
digested with RNaseA and proteinase K. From the purified DNA
sequencing, libraries were generated with the NEBNext Ultra library
preparation kit (NEB). ChIP-seq of both CTCF and EBF1 was
done with the SimpleChIP-seq kit from Cell Signaling Technology
according to the manufacturer’s instructions. After purification of
the DNA, libraries were cloned with the NEBNext Ultra II library kit
(NEB). The antibodies used for ChIP-seq were H3K4me1 (Abcam
ab8895), H3K4me3 (Abcam ab8580), H3K9ac (Active Motif 39137),
H3K9me3 (Abcam ab8898), H3K27ac (Abcam ab4729), H3K27me3
(Abcam ab6002), H3K36me3 (Abcam ab9050), H3 (Abcam ab1791),
CTCF (Active Motif 61311), and EBF1 (Sigma SAB2501166) and are
listed in Appendix Table S4.
ATAC-seq
Nuclei from formaldehyde-fixed or viable frozen (one out of seven
NBC samples) cells were isolated with Nuclei EZ lysis buffer
(Sigma-Aldrich), washed once in ATAC-seq lysis buffer (10 mM
Tris–HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, and 0.1% IGEPAL
CA-630) and incubated with Tn5 transposase (Illumina) for 30 min
at 37°C or viable frozen cells (three out of seven NBC samples) were
directly incubated with Tn5 for 30 min at 37°C in the presence of
0.1% Igepal CA-630 (Sigma-Aldrich). After incubation, Tn5 was
stopped with EDTA, for previously fixed samples, cross-links were
reversed, and the DNA was purified with AMPure beads (Beckman
Coulter). Barcodes were added by PCR, and the libraries were puri-
fied again with AMPure beads. The scATAC-seq sequencing libraries
were generated with the Fluidigm C1 system as described previously
(Buenrostro et al, 2015). In brief, viably frozen, primary B cells
were loaded on a 96-chamber C1 flow cell and captured cells were
analyzed by microscopy to exclude doublets. After harvesting the
pre-amplified single-cell ATAC-seq libraries, dual external barcodes
were added by PCR and all libraries from one C1 flow cell were
pooled. Libraries were 50-bp paired-end sequenced on Illumina
HiSeq 2000 (all scATAC-seq samples) or 4000 systems.
RNA-seq
For RNA-seq, short and long RNA fractions were isolated with the
miRNeasy Mini Kit (Qiagen), RNA was digested by DNase I
(Promega) for 30 min at 37°C and depleted from rRNA with Ribo-
Zero Gold, and finally, directional cDNA synthesis and sequencing
library preparation were conducted according to the NEBNext Ultra
Directional RNA Library Prep Kit (NEB). All libraries were 50-bp
single-end sequenced on the HiSeq 2000 machine.
Panobinostat treatment and HDAC activity assay
Primary CLL cells from three treatment-naı¨ve patients and NBCs in
a pool of 28 healthy donors were treated with 5 nM panobinostat
(Biozol) ex vivo. Cells were sampled before as well as 2 and 24 h
after initiation of treatment. Western blots were conducted to evalu-
ate changes in the abundance of H3K9ac and H3K27ac. The samples
were subject to ChIP-seq experiments for seven histone modifi-
cations and the H3 control and also to RNA-seq as described below.
Malignant and NBCs of each of four individual CLL patients or
healthy donors, respectively, were enriched for CD19-positive. A
total of 10,000 cells were seeded in serum-free medium and incu-
bated for 30 min with DMSO as mock control or different concentra-
tions of panobinostat (25 pM–250 nM). HDAC-Glo I/II assay
(Promega) was performed in technical triplicates according to
manufacturer’s protocol and measured with the Promega GloMax
device.
DNA methylation analysis
Whole-genome bisulfite sequencing data were processed with
MethylCtools as previously described (Hovestadt et al, 2014). In
addition to the default pipeline of MethylCtools, an updated version
of BWA-MEM (v0.7.12-r1039) was used to align reads to the human
reference genome, build hg19 (hs37d5) from the 1000 Human
Genome project (Li & Durbin, 2010). DNA methylation levels (b-
values) were calculated for more than 23 million CpG sites covered
with at least five reads and supported to be a correct CpG by the
sequencing data in individual samples (> 75% of reads; Hovestadt
et al, 2014). The non-conversion rates were below 0.25% for all
samples as determined from the spiked-in lambda phage genome
DNA. Partially methylated domains were identified for each sample
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using an approach described previously (Berman et al, 2011; Hoves-
tadt et al, 2014). In brief, the genome was scanned with a
10-kb sliding window (R caTools package, v1.17.1) to retrieve
windows with average methylation levels < 0.65. The resulting
10-kb windows were joined together if overlapping, and the merged
regions over 100 kb were called as partially methylated domains.
The consensus PMDs were generated as the union of PMDs present
in at least half of the CLL samples analyzed (≥ 6). Differentially
methylated regions between CLL and NBCs were identified using
the R Bioconductor (Gentleman et al, 2004) package, DSS (v2.10.0;
Feng et al, 2014), and P < 0.05, the minimum length of 200 base
pairs and the differential methylation threshold of 0.3. The DMRs
and PMDs overlapping with the UCSC “gap” table, comprising
centromeres, telomeres or regions with no sequence information,
were discarded from further analysis. Normal B-cell programming
might account for some of the methylation changes from the
comparison of CLL to NBCs (Oakes et al, 2016). To account for this,
DMRs were filtered out if they show “similar” methylation changes
(< 0.2 b-value) also in the comparison of high-maturity memory B
cells to naive B cells as described previously (Oakes et al, 2016).
Methylation profiles were employed to assign CLL samples into
three distinct CLL subtypes (low, intermediate, and high)
programmed using a reference 450K methylation data from 185 CLL
cases. Raw 450K data were processed using the Minfi Bioconductor
package (v1.16.1; Aryee et al, 2014). Phylogenetic analysis was
carried out as previously reported (Brocks et al, 2014; Oakes et al,
2016) on the 450K data of CLL cases and normal B-cell subsets
together with the WGBS data of CLL cases from our study. As a vali-
dation, a support vector machine (SVM) model (Queiros et al, 2015)
was adopted to classify CLL samples into three distinct subtypes,
confirming our previous results. To exclude any label switching,
genetic fingerprinting was performed to all the samples profiled by
WGBS, ChIP-seq, ATAC-seq, and RNA-seq, validating the sample
origin.
ChIP-seq data analysis
After mapping with bowtie to the hg19 genome assembly with
decoy regions (options –best -strata -v 1 -m 1), peaks were called
with MACS for H3K4me1, H3K4me3, H3K9ac, and H3K27ac using
H3 as a background control. For H3K9me3, H3K27me3, and
H3K36me3, SICER was used to determine enriched regions with
histone H3 serving again as a control. In order to computationally
validate the quality of the ChIP-seq experiments, we clustered the
different IP samples using their Pearson correlation. Additionally,
quality scores suggested by the ENCODE project were used to assess
the overall quality of each ChIP-seq data set (Dataset EV4). Peaks
were then used for chromatin state analysis with ChromHMM as
stated below. Topology and size distributions of modified chromatin
regions were calculated with MCORE as described in Molitor et al
(2017) with the modification that histone H3 was used as a back-
ground file for normalization. CTCF and EBF1 ChIP-seq sequencing
libraries were mapped as described above, and peaks were called
with MACS2 using standard parameters for narrow peak detection.
Differential histone modification and TF binding analysis from
ChIP-seq data were performed using the peaks called for each
sample and the corresponding reads counts within the alignment
files using DiffBind (Dataset EV8). Read counts were scaled to the
control, and normalization was done relative to the number of reads
within peak regions. Differential enhancers were called using edgeR
with an FDR threshold of 0.01 within DiffBind. For the 24-h mock
treatment and panobinostat samples, paired analysis was performed
using DESeq2 with an FDR threshold of 0.01 within DiffBind.
The panobinostat differential H3K27ac regions were annotated
as promoter overlapping with respect to any TSS from Gencode v17
and annotated as enhancer overlapping with respect to the enhan-
cers of combined CLL occurring in at least three untreated or two
24-h-treated samples. For both CTCF and EBF1, differential regions
between CLL and NBCs were computed form a consensus peak list
within DiffBind.
Genome segmentation and chromatin annotation
The chromatin was segmented and annotated using a multivariate
Hidden Markov model with the ChromHMM software (Ernst &
Kellis, 2012). The model was trained using seven histone modifi-
cation marks (H3K4me1, H3K4me3, H3K27ac, H3K27me3, H3K9ac,
H3K9me3, and H3K36me3) across all samples where histone modi-
fication ChIP-seq data were of sufficient quality for all histone
marks (samples H1, H3–5, H8, CLL1–3, CLL5–11). The model was
learned by using the merged peak called with MACS or SICER from
the ChIP-seq data as binarized input for ChromHMM and allowing
for a maximum of 400 iterations. We generated and compared
models with 7–50 states and decided to use 12 states (Datasets EV6
and EV7). This model captured all combinations of biologically
interpretable states with median correlation of 0.72 to the 50-state
model and displayed high concordance with the Roadmap 15-state
model. For further analysis, the 12-state ChromHMM model was
used to segment the genome of each individual sample (including
the panobinostat-treated samples not used for generating the
model).
Nucleosome occupancy maps
Paired-end sequenced histone H3 ChIP-seq libraries from MNase-
digested chromatin were used to determine nucleosome positions in
malignant and NBCs. Reads were mapped with Bowtie as described
above and processed using NucTools (Vainshtein et al, 2017) to
generate genome-wide nucleosome occupancy landscapes, extract
individual genomic regions, and calculate the nucleosome repeat
length, as described previously (Teif et al, 2012, 2014; Vainshtein
et al, 2017). Aggregate nucleosome occupancy profiles around
genomic features were calculated using HOMER (Heinz et al, 2010)
and NucTools (Vainshtein et al, 2017). The pathway enrichment
analysis was performed with DAVID and EnrichR.
ATAC-seq data analysis
Both scATAC-seq and bulk ATAC-seq were processed in a similar
manner. Reads were trimmed using Trimmomatic version 0.36 (Bol-
ger et al, 2014) and mapped to the human genome (hs37d5) using
bowtie2 (Langmead et al, 2009) with the options “–very-sensitive -X
2000”. After removing reads which in regions blacklisted by
ENCODE (https://sites.google.com/site/anshulkundaje/projects/
blacklists), duplicate reads were discarded using rmdup of SAMtools
version 1.3 (Li et al, 2009) and reads mapping to the mitochondrial
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genome were also removed. For further analysis and calculation of
coverage tracks, all reads were shifted to be centered on the cutting
position of the transposase and extended to a total of 29 bp to repre-
sent the region occupied by the transposase (Adey et al, 2010). For
bulk ATAC-seq, peak calling was done with MACS2 version 2.1.1
(Zhang et al, 2008) with the parameters “–nomodel –shift -10 –
extsize 28 –broad”. Differential ATAC-seq signals were calculated
with DiffBind (Ross-Innes et al, 2012), within peak regions called in
at least four replicates (Dataset EV10.1). Fold change thresholds
were determined as the intersections of three Gaussian functions fit-
ted to the distribution of log2 fold changes from DiffBind
(Fig EV1E). The FDR threshold used for the differential ATAC-seq
signal analysis was set to the x-value of the inflection point of the
number of differentially accessible regions as function of FDR
threshold. The analysis was also conducted with only fixed frozen
NBC samples to ensure that the results were not affected by dif-
ferences between fixed and viably frozen control samples (Dataset
EV10.2, used for TF motif analysis in Appendix Fig S5A and B).
For scATAC-seq, typically 40,000–100,000 unique integrations
per cell were obtained. Cells with very few (less than 0.2-times the
average) or very frequent (more than three standard deviations
above the average) integrations were removed from the analysis.
Variations in accessibility for different TF binding motifs were deter-
mined with chromVAR (Schep et al, 2017). Correlation coefficients
for simultaneous insertions across all cells at promoters and enhan-
cers were computed with the R-package RWire, which has been
deposited at https://github.com/FabianErdel/RWire. Target promot-
ers of enhancers within TAD-sized regions were identified based on
the respective correlation values using a threshold (0.22) derived
from the spurious correlations obtained after randomly permuting
insertions (see Appendix Fig S6 for details). The resulting set of
promoter–enhancer pairs was used for downstream analysis and
integrated into the gene regulatory network.
Enhancer annotation
Different sets of putative enhancers in CLL and NBCs were compiled
that all excluded promoter regions as defined by a region of  1 kb
around the TSS (RefSeq): (i) In order to identify TF motifs gained or
lost in CLL within the ATAC peak regions, the differential ATAC
signal was intersected with either all four potential enhancer
containing ChromHMM states 1, 8, 9, and 11 (Fig 5A and C) or only
with the predicted active enhancer states 1 and 9, which carry a
strong H3K27ac signal (Appendix Fig S5A) or with the predicted
poised/weak enhancers from states 8 and 11 (Appendix Fig S5B).
(ii) Active enhancer lists were based on either ATAC signal or bidi-
rectional transcription (Bidi) as active marks. ATAC-seq peaks or
sites of bidirectionally expressed RNA loci identified in both repli-
cates of a given patient or NBC control sample were selected. A
 1 kb region around the ATAC/Bidi signal center was intersected
with the predicted intergenic and genic active enhancer states 1 and
9. The size of  1 kb was selected based on the average extension
of key enhancer marks (H3K27ac, H3K4me1, p300, Bidi; Chen et al,
2018). Subsequently, overlapping regions were merged. Consensus
active enhancer lists for CLL and NBCs were generated from individ-
ual patient or NBC control lists by selecting regions which were
identified in at least three of the available CLL patient sample and
one (ATAC) or two (Bidi) of the NBC controls, for which both the
ChromHMM annotation and ATAC-seq/Bidi data were available.
(iii) SEs were predicted with the ROSE tool (Whyte et al, 2013) by
using the H3K27ac read signal within the overlap region of ATAC
and H3K27ac peaks. The Gencode v17 genes were defined as a
background gene model for filtering transcription start sites within
ROSE. Differential analysis of H3K27ac at enhancers was performed
using DiffBind on the enhancer regions occurring in at least three
samples with the original H3K27ac data for the individual samples.
Differential loci were called using DiffBind with an FDR threshold of
0.01. Functional assignment of differential SEs was done with
GREAT (McLean et al, 2010) with modified parameters of 10 kb
upstream, 5 kb downstream, and 2 Mb distal which annotates
cis-regulatory regions.
TF motif analysis
To identify TF motifs in regions of interest with gained or lost
occupancy, we used the HOMER package with appropriate back-
ground controls for each individual data set (Heinz et al, 2010).
All TF motif analysis was conducted within the ATAC peak
regions. For the TF footprinting analysis, loci with a certain motif
were retrieved with HOMER’s “annotatePeaks.pl” and “known
motifs” analysis. Coverage tracks  100 bp around the center of
the motifs were generated with ngs.plot (Shen et al, 2014) using
combined reads from all CLL patients or NBC controls collapsed to
the center of the transposase binding event. In Appendix Table S2,
the TF sequence-binding motifs and selected factors are listed that
were associated with at least one additional aberrant chromatin
feature in CLL in addition to chromatin accessibility changes as
detected by ATAC-seq. These chromatin features included histone
H3K4me3 broadening, nucleosome gain or loss of the bivalent
H3K4me3-H3K27me3 mark at promoters, or, at enhancers, dif-
ferential DNA methylation or H3K27ac changes. Only TFs were
included that showed a significant differential protein activity (or
gene expression for network target genes) as computed from our
B-cell-specific gene regulatory network (Fig 1E). The latter served
to select specific TFs from TF families that recognize the same
DNA sequence motif. For example, a number of the ETS family
TFs recognize the same sequence motif (Wei et al, 2010) but
many of these TFs did not display differential activity as computed
from their target gene expression data.
RNA-seq data analysis
Sequence reads were mapped to the human genome (hs37d5,) using
STAR version 2.3.0 (Dobin et al, 2013) with the parameters: –genome-
Load LoadAndRemove –alignIntronMax 500000 –alignMatesGapMax
500000 –outSAMunmapped Within –outFilterMultimapNmax 1 –
outFilterMismatchNmax 3 –outFilterMismatchNoverLmax 0.3 –
sjdbOverhang 50 –chimSegmentMin 15 –chimScoreMin 1 –chimS-
coreJunctionNonGTAG 0 –chimJunctionOverhangMin 15. RPKM
and TPM values were computed for the long and the total RNA. The
mapped reads were quantified using HTSeq-count from the HTSeq
framework version 0.6.0 using the intersection_nonempty option in
a stranded fashion according to the gencode17 annotation (Anders
et al, 2015). Normalization and differential expression analysis were
performed using DESeq2 (Love et al, 2014; Dataset EV11). Bidirec-
tional expression was computed within a 1-kb sliding window. Loci
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were selected that had at an expression level of at least 20% of the
reads of the higher transcribed strand produced from the other
strand and displaying a bimodal shape of the differently directed
reads. Regions overlapping transcription start sites or exons on both
strands were excluded.
Gene regulatory network construction and activity calculation
A human B-cell regulatory network was constructed from 264
publicly available samples (Basso et al, 2010) including normal B
cells, B-cell lymphomas, and cell lines by using the ARACNe-AP
algorithm (Lachmann et al, 2016) with default parameters (MI
P = 108, 100 bootstraps, and permutation seed = 1). Regulatory
proteins were taken from a previously compiled list of 5,927
proteins (TFs, transcriptional co-factors, and signaling pathway-
related genes etc.) based on gene ontology annotations (Alvarez
et al, 2016). From this list, 3,862 proteins were present in the B-cell
network, which additionally contained 12,119 target genes and
214,405 interactions. The average and median of target genes per
regulator were 56 and 45, respectively. The activity values of regu-
lators were calculated based on our RNA-seq data set by using the
VIPER algorithm (Alvarez et al, 2016). For this, the raw RNA-seq
counts were normalized by variance-stabilizing transformation
using DESeq2 (Love et al, 2014). Activities for 2,804 of the 3,862
regulators could be computed. To identify regulators which showed
a significantly different activity between the CLL samples and the
NBC samples, a two-sided Student’s t-test was performed and the
P-values were adjusted for multiple testing (Benjamini & Hochberg,
1995) yielding 1,378 differentially active regulators with an
adjusted P-value < 0.05. Differential expression of regulators target
genes of the regulators was determined with DESeq2. Gene set
enrichment analysis was performed using the R-package “gPro-
fileR” (Reimand et al, 2016) with the B-cell network as universe to
identify significantly enriched KEGG pathways (Kanehisa & Goto,
2000) for the identified core TFs and their target genes. The
network was visualized using Cytoscape version 3.5.1 (Shannon
et al, 2003). Regulators with a differential activity change between
the CLL and the NBC samples (P < 0.05) and all differential
expressed non-regulators (P < 0.01) with a log fold change of
1.7 < LFC > 1.7 were selected for further analysis. To identify
aberrant chromatin modifier in CLL vs. NBCs, the list of deregu-
lated regulators/genes was intersected with the EpiFactors database
(Medvedeva et al, 2015). This list was then reduced to those genes
that were linked to the deregulated chromatin features identified in
our study (meC loss, H3K27me3 gain, H3K27ac loss/gain, and
H3K4me3 loss/gain).
All enhancer–promoter pairs with a correlation of 0.22 or higher
in the scATAC-seq analysis (Appendix Fig S6D and F) were used
from the CLL and the NBC samples. To remove duplicates, overlap-
ping regions were put together and the gene promoters were
mapped to gene symbols. The enhancer–promoter pairs were
grouped into CLL only (C), NBCs only (H), and found in both
groups (CH). For all these cases, the enhancers were numbered
consecutively (C1-C1208 in case of the CLL-specific enhancers) and
the information about the genomic positions was added as a node
attribute. For all the genes in the B-cell network, the enhancer–gene
interactions were integrated. For the CLL-specific network, the
interactions between the core TFs (Appendix Table S2), their dereg-
ulated target genes, and the selected chromatin modifier as well as
the enhancers were extracted from the B-cell network (Datasets
EV13 and EV14). Exemplarily, the part of the network around TCF4
and EBF1 is shown in Fig 6D. In Appendix Fig S7, the linked part
around the core TFs is shown, and here, some chromatin modifiers
were grouped into complexes.
Data availability
The data and computer code produced in this study are available
from the following sources:
All original sequencing data have been deposited at European
Genome-phenome Archive under the accession number EGAS00001002518
(http://www.ebi.ac.uk/ega/).
Processed WGBS, ChIP-seq, (sc)ATAC-seq, and RNA-seq data are
available under GSE113336 (https://www.ncbi.nlm.nih.gov/ge
o/query/acc.cgi?acc=GSE113336) at Gene Expression Omnibus as
full bigBed/BigWig files.
Metadata from the comprehensive analyses are provided as
Datasets EV1–EV14 with the manuscript. They are described in
Appendix Table S6, and additional data are available via the web
page http://www.cancerepisys.org/data/cancerepisys_data/.
Software used for the data analysis for the different sequencing
readouts is listed in Appendix Table S7. Custom analysis scripts and
tools are available from Github at https://github.com/Cance
rEpiSys/Mallm-et-al-processing-scripts, and the R-package RWire
has been deposited at https://github.com/FabianErdel/RWire.
Expanded View for this article is available online.
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